Pharmacotherapeutic Management of Wilms Tumor: An Update

Oostveen, R. M.; Pritchard‐Jones, Kathy

doi:10.1007/s40272-018-0323-z

Cited by 26 publications

(22 citation statements)

References 89 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Overall, because DNA methylation constitutes a mechanism of gene expression control, systematic investigations on how cancer cells exploit this mechanism to deregulate specific targets and processes can help us to understand the disease manifestation, by capturing and functionally implicating cancer-associated methylation events and exploiting the therapeutic opportunities [62]. In WT, the response of the lung nodules to chemotherapy is used to modify treatment intensity, with the use of an additional agent, Irinotecan, being explored as a new strategy for metastatic and relapsed WT [63].…”

Section: Discussionmentioning

confidence: 99%

Genes Controlled by DNA Methylation Are Involved in Wilms Tumor Progression

Guerra

Pereira

Cruz

et al. 2019

Cells

View full text Add to dashboard Cite

To identify underlying mechanisms involved with metastasis formation in Wilms tumors (WTs), we performed comprehensive DNA methylation and gene expression analyses of matched normal kidney (NK), WT blastemal component, and metastatic tissues (MT) from patients treated under SIOP 2001 protocol. A linear Bayesian framework model identified 497 differentially methylated positions (DMPs) between groups that discriminated NK from WT, but MT samples were divided in two groups. Accordingly, methylation variance grouped NK and three MT samples tightly together and all WT with four MT samples that showed high variability. WT were hypomethylated compared to NK, and MT had a hypermethylated pattern compared to both groups. The methylation patterns were in agreement with methylases and demethylases expression. Methylation data pointed to the existence of two groups of metastases. While hierarchical clustering analysis based on the expression of all 2569 differentially expressed genes (DEGs) discriminated WT and MT from all NK samples, the hierarchical clustering based on the expression of 44 genes with a differentially methylated region (DMR) located in their promoter region revealed two groups: one containing all NKs and three MTs and one containing all WT and four MTs. Methylation changes might be controlling expression of genes associated with WT progression. The 44 genes are candidates to be further explored as a signature for metastasis formation in WT.

show abstract

Section: Discussionmentioning

confidence: 99%

Genes Controlled by DNA Methylation Are Involved in Wilms Tumor Progression

Guerra

Pereira

Cruz

et al. 2019

Cells

View full text Add to dashboard Cite

show abstract

“…Diazoxide is the first choice for treating CHI. It is a nondiuretic benzothiadiazine originally formulated as a peripheral vasodilator to reduce severe hypertension by smooth muscle relaxation [9]. It was first used to treat CHI in the 1960s [10] and has been the primary treatment since then.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of diazoxide for treating hyperinsulinemic hypoglycemia: A systematic review and meta-analysis

et al. 2021

View full text Add to dashboard Cite

Diazoxide is the first-line drug for treating hyperinsulinism and the only pharmacological agent approved for hyperinsulinism by the Federal Drug Administration. This systemic review and meta-analysis aimed to investigate the efficacy and safety of diazoxide for treating hyperinsulinemic hypoglycemia (HH). The meta-analysis of the efficacy and safety of diazoxide in treating HH was performed by searching relevant studies in the PubMed, Embase, and Cochrane databases. The findings were summarized, and the pooled effect size and its 95% confidence interval (CI) were calculated. A total of 6 cohort studies, involving 1142 participants, met the inclusion criteria. Among the cohort studies, the pooled estimate of the response rate of diazoxide therapy was 71% (95% CI 50%–93%, Pheterogeneity< 0.001, I2 = 98.3%, Peffect< 0.001). The common side effects were hypertrichosis (45%), fluid retention (20%), gastrointestinal reaction (13%), edema (11%), and neutropenia (9%). Other adverse events included pulmonary hypertension (2%) and thrombocytopenia (2%). This meta-analysis suggested that diazoxide was potentially useful in HH management; however, it had some side effects, which needed careful monitoring. Furthermore, well-designed large-scale studies, such as randomized controlled trials, might be necessary in the future to obtain more evidence.

show abstract

“…It is expected that in 2030, 21 million people worldwide will suffer from cancer [ 2 ]. Tremendous progress, however, has been made in the treatment of individual cancers [ 3 , 4 , 5 , 6 ]. This is due, on one hand, to improved early detection and prophylaxis and, on the other, to the development of highly efficient drugs in a wide range of different substance classes.…”

Section: Introductionmentioning

confidence: 99%

Mitocanic Di- and Triterpenoid Rhodamine B Conjugates

et al. 2020

View full text Add to dashboard Cite

The combination of the “correct” triterpenoid, the “correct” spacer and rhodamine B (RhoB) seems to be decisive for the ability of the conjugate to accumulate in mitochondria. So far, several triterpenoid rhodamine B conjugates have been prepared and screened for their cytotoxic activity. To obtain cytotoxic compounds with EC50 values in a low nano-molar range combined with good tumor/non-tumor selectivity, the Rho B unit has to be attached via an amine spacer to the terpenoid skeleton. To avoid spirolactamization, secondary amines have to be used. First results indicate that a homopiperazinyl spacer is superior to a piperazinyl spacer. Hybrids derived from maslinic acid or tormentic acid are superior to those from oleanolic, ursolic, glycyrrhetinic or euscaphic acid. Thus, a tormentic acid-derived RhoB conjugate 32, holding a homopiperazinyl spacer can be regarded, at present, as the most promising candidate for further biological studies.

show abstract

Pharmacotherapeutic Management of Wilms Tumor: An Update

Cited by 26 publications

References 89 publications

Genes Controlled by DNA Methylation Are Involved in Wilms Tumor Progression

Genes Controlled by DNA Methylation Are Involved in Wilms Tumor Progression

Efficacy and safety of diazoxide for treating hyperinsulinemic hypoglycemia: A systematic review and meta-analysis

Mitocanic Di- and Triterpenoid Rhodamine B Conjugates

Contact Info

Product

Resources

About